[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hospital San Carlos, Madrid\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":320},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,51,85,116,143,171,205,235,270,297],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100524838","phase-4-prevention-of-infection-of-the-respiratory-tract-through-application-of-non-invasive-methods-of-secretion-suctioning-100524838",false,"NCT06113939","Prevention of Infection of the Respiratory Tract Through Application of Non-Invasive Methods of Secretion Suctioning","Prevention of Infection of the Respiratory Tract by Applying Methods That Are Non-Invasive for Extraction of Secretions. An Open Label, Randomized, Assessor-blinded, Pilot Trial.","PIRAMIDES","Inclusion criteria\n\n1. Endotracheal intubation with an anticipated duration \\> 48 hours.\n2. High risk of early respiratory infection associated with a diagnosis of:\n\n   1. Severe trauma.\n   2. Severe traumatic brain injury.\n   3. Ischaemic or haemorrhagic stroke.\n   4. Other causes of impaired consciousness: post-resuscitated cardiac arrest status, intoxications, acute infections or diseases of the central nervous system, seizures.\n3. Informed consent signed by the patient or, when impossible due to clinical status, by their legal representative, with re-consent by the patients themselves upon regaining capacity (section 15).\n\nExclusion criteria\n\n1. Intubation with an anticipated duration \\\u003C 48 hours.\n2. Foreseeable ominous prognosis within \\\u003C 7 days.\n3. Already established indication for systemic antibiotic therapy, either for suspected aspiration pneumonia with radiological pulmonary infiltrate or for suspected non-respiratory source infection.\n4. Active haemoptysis or pulmonary haemorrhage.\n5. Unstable chest.\n6. Undrained pneumothorax (inclusion may be considered once drained).\n7. Known allergy or intolerance to beta-lactam antibiotics.","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Adults who are unconscious or severely ill and need a breathing tube connected to a ventilator are at high risk of developing a lung infection (pneumonia) within the first few days in the intensive care unit. This early pneumonia affects up to 30 to 50 % of certain high-risk patients, prolongs the time on the ventilator and in hospital, and increases the use of antibiotics.\n\nTwo strategies are commonly used today to try to prevent this infection: a short, three-day course of an intravenous antibiotic, and removal of secretions from the airway with a sterile suction catheter. Both have limitations - antibiotics can favour the growth of resistant bacteria, and catheter suctioning is uncomfortable and may injure the airway.\n\nPIRÁMIDES is a small (60-patient) pilot study that compares the current practice with two non-invasive, mechanical alternatives for keeping the airway clear: a continuous low-pressure suction system built into a special breathing tube, and a device that produces a gentle, programmed \"artificial cough\" through the ventilator. Adult patients who are intubated for severe trauma, severe brain injury, stroke, resuscitated cardiac arrest or other causes of decreased consciousness are randomly assigned, in equal numbers, to one of the three approaches and followed for 14 days, with a final visit at day 90.\n\nThe main goal is to find out which of the three strategies best prevents early pneumonia, and which provides the best overall result for patients when survival, severity of infection, need for additional antibiotics and side effects are considered together. To make these comparisons as fair as possible in an open-label study, an independent committee of doctors not involved in patient care reviews each suspected pneumonia case without knowing which strategy the patient received. The results will help design a larger trial to confirm which approach is safest and most effective for preventing early pneumonia in critically ill patients on a ventilator.",[27,28,29,30,31,32,33],"Intubation Complication","Stroke, Ischemic","Stroke Hemorrhagic","Head Trauma","Cardiac Arrest","Ventilator Associated Pneumonia","Airway Clearance Impairment",[35,36,37],"ventilator-associated pneumonia","prevention","airway clearance","NOT_YET_RECRUITING","2026-06-25",{"date":41,"type":42},"2026-06-29","ACTUAL",{"date":44,"type":21},"2026-09-15",{"date":46,"type":21},"2029-06-30",{"name":48,"class":49},"Hospital San Carlos, Madrid","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":68,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":50},"100643324","structured-nursing-intervention-for-adults-with-poorly-controlled-asthma-a-pilot-study-100643324","NCT07635537","Structured Nursing Intervention for Adults With Poorly Controlled Asthma: A Pilot Study","Design and Development of RESPiraIA-Asthma: A Structured Nursing Intervention for the Follow-up of Adults With Poorly Controlled Asthma. A Pilot Study","RESPiraIA-Asma","Inclusion Criteria:\n\n* Confirmed diagnosis of mild or moderate persistent, non-severe asthma.\n* Poorly controlled asthma, defined as an Asthma Control Test (ACT) score below 20.\n* Active inhaled maintenance therapy with inhaled corticosteroids (ICS), alone or combined with a long-acting beta-agonist (LABA).\n* Age 18 years or older.\n* Active follow-up in the Pulmonology outpatient clinic of Hospital Clínico San Carlos.\n* Sufficient cognitive capacity to participate and complete the questionnaires.\n* Access to a means of communication (in-person, telephone, digital, or mixed).\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Significant respiratory comorbidity (chronic obstructive pulmonary disease ( COPD), bronchiectasis, pulmonary fibrosis, chronic pulmonary thromboembolism, or home oxygen therapy).\n* Acute asthma exacerbation within the 4 weeks before inclusion.\n* Participation in another clinical trial within the previous 12 months.\n* Cognitive impairment or language barriers preventing completion of the questionnaires.\n* Conditions limiting continuity of follow-up over the 12 months.\n* Mild comorbidities such as allergic rhinitis or mild sleep apnea are not exclusion criteria.",{"count":60,"type":21},30,[62],"NA","Asthma affects a large number of adults, and many of them do not achieve good control of their symptoms. Poor inhaler technique, irregular medication use, and the lack of structured nursing follow-up are among the main reasons. RESPiraIA-Asma is a 12-month structured nursing intervention designed to address these gaps in adults with poorly controlled, non-severe asthma.\n\nThis is a quasi-experimental, single-group, before-and-after pilot study. Each participant is followed across six visits over one year, at baseline and at months 1, 3, 6, 9, and 12. The intervention combines therapeutic education, inhaler technique training, home peak-flow self-monitoring, biopsychosocial assessment, and a standardized nursing care plan based on internationally recognized nursing taxonomies for diagnoses, interventions, and outcomes: NANDA International (NANDA-I), Nursing Interventions Classification (NIC), and Nursing Outcomes Classification (NOC), activated by objective clinical thresholds.\n\nA central principle of the model is digital equity: the same standard of care is offered through three equivalent access routes (digital, mixed, or in-person), chosen according to each participant's digital skills, resources, and preferences, so that technology never becomes a barrier to access.\n\nThe study evaluates whether the model is feasible to deliver in routine clinical practice, measured through participant retention, data completeness, and acceptability, and it looks for preliminary signals of its effect on asthma control, treatment adherence, lung function, and biopsychosocial well-being. As an exploratory pilot, it is not designed to confirm efficacy; its purpose is to inform the design of a larger future trial.",[65,66,67],"Asthma","Medication Adherence","Self-management",[65,69,70,71,72,73,74,75,76],"Nursing Diagnosis","Treatment Adherence and Compliance","Nursing Care","Digital Divide","Digital Technology","Artificial Intelligence","Structured nursing intervention","NANDA-I, NIC, NOC","2026-06-03",{"date":79,"type":42},"2026-06-09",{"date":81,"type":21},"2026-10",{"date":83,"type":21},"2029-09",{"name":48,"class":49},{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":50},"100605107","long-term-effect-of-brain-stimulation-in-ppa-100605107","NCT07158216","Long Term Effect of Brain Stimulation in PPA","Long-term Effect of Transcranial Magnetic Stimulation and Transcranial Electrical Stimulation in Primary Progressive Aphasia: Randomized, Double-blind Clinical Trial (RECONNECT-PLUS)","RECONNECT-PLUS","Inclusion Criteria:\n\n* Diagnosis of PPA according to the current consensus criteria proposed by Gorno-Tempini et al., 2011), based on the presence of progressive language impairment as the most prominent and primary cause of functional decline and the exclusion of other medical, psychiatric, or non-neurodegenerative causes,a s well as early prominent memory, visuoperceptual or behavioral disturbances;\n* Diagnosis of one of the three variants of PPA (non-fluent, semantic, or logopenic) according to the consensus criteria (Gorno-Tempini et al., 2011), based on the language profile and supported by neuroimaging (FDG-PET or MRI).\n* Clinical Dementia Rating scale equal or less than 1;\n* The language impairment is the main neurological deficit for the patient.\n\nExclusion Criteria:\n\n* Patient diagnosed with a condition other than PPA that could cause language impairment;\n* History of epilepsy or presence of focal epileptiform pathology on EEG recording; ·Contraindications related to the treatments or procedures to be used (TMS and tDCS), such as ferromagnetic material, pregnancy, or breastfeeding;\n* Terminal illness or active malignancy;\n* Alcohol or substance abuse within the past year;\n* Major psychiatric disorders (schizophrenia, schizoaffective disorders, bipolar disorder, obsessive-compulsive disorder, or personality disorders);\n* Absolute inability to communicate (mutism), or poor command of the language that, in the investigator's judgment, would prevent participation in the study;\n* Severity of PPA that prevents participation in interventions or assessments at the time of inclusion;\n* Participation in another clinical trial within the previous 4 months;\n* Chronic use of medications that could affect study outcomes;\n* Antiepileptic drugs: allowed if on stable doses for at least 3 months before inclusion. If needed during the study due to seizure occurrence, they may be added;\n* Diazepam and derivatives: permitted only if on stable doses for at least 3 months before inclusion. Dose adjustments during the study are allowed;\n* Donepezil, Galantamine, Rivastigmine, and Memantine: allowed if on stable doses for at least 3 months before inclusion;\n* SSRIs (Selective Serotonin Reuptake Inhibitors): permitted only if on stable doses for at least 3 months prior to inclusion. If necessary during the study, they may be added;\n* Medications that may lower the seizure threshold (e.g., tricyclic antidepressants, antipsychotics): allowed if on stable doses for at least 3 months before inclusion.",{"count":94,"type":21},80,[62],"The goal of this clinical trial is to investigate the effect of non-invasive brain stimulation techniques in the progression of primary progressive aphasia for 6 months. We will compare three modalities of brain stimulation (TMS, tDCS, TMS+tDCS) against sham stimulation. All patients will receive also language therapy.",[98],"Primary Progressive Aphasia(PPA)",[100,101,102,103,104,105,106],"Primary progressive aphasia","Frontotemporal dementia","Alzheimer's disease","Brain stimulation","Transcranial Magnetic Stimulation","Transcranial direct current stimulation","Transcranial electrical stimulation","RECRUITING","2026-04-19",{"date":110,"type":42},"2026-04-23",{"date":112,"type":42},"2025-09-15",{"date":114,"type":21},"2028-12",{"name":48,"class":49},{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":127,"conditions":128,"keywords":132,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":50},"100622942","ablation-of-human-cardiac-fibrillation-based-on-models-of-hierarchical-organization-of-tissue-excitation-100622942","NCT07390175","Ablation of Human Cardiac Fibrillation Based on Models of Hierarchical Organization of Tissue Excitation","Ablación de la fibrilación Cardiaca Humana Basada en Modelos de organización jerárquica de la excitación Tisular.","TerFib","Inclusion Criteria:\n\n* Patients over 18 years of age with persistent AF lasting more than 6 months at the time of the experimental protocol (uninterrupted persistent AF) and clinical indication for an AF ablation procedure.\n\nor\n\n-Patients over 18 years of age with recurrent VF\u002FVT and poor control with conventional pharmacological measures.\n\nExclusion Criteria:\n\n* Lack of patient consent to participate in the study.\n* In patients with persistent AF, contraindication for the use of adenosine.\n* AF\u002FVF\u002FVPT secondary to endocrine-metabolic disorders and\u002For severe systemic disease (thyrotoxicosis, sepsis, pulmonary thromboembolism, etc.).\n* Contraindications for cardiac catheterization (e.g., intracardiac thrombus).\n* Impossibility of remote monitoring using an implantable Holter monitor or implantable defibrillator.",{"count":125,"type":21},78,[62],"The mechanisms that maintain persistent atrial fibrillation (AF) in humans remain unknown. In the research project PI18\u002F01268 funded in the previous call for Strategic Action in Health, the group has demonstrated that the hierarchical organization of (i) rotational domains, (ii) frequency domains and (iii) physiological responses to pharmacological provocation with adenosine, allow the identification of domains of high-frequency reentrant activity (hereinafter \"DFASI domains\") maintainers of AF. As a result, the investigators have developed non-invasive technological models and quantitative indices for the efficient localization of these domains, whose therapeutic approach through ablation has allowed to improve the clinical results of the patients studied, safely without increase in complications (Calvo D et al. Sci Rep. 2025 Dec 16;15(1):43892). Likewise, and in response to the objectives of the PI18\u002F01268 project, the investigators have identified hierarchical organization patterns in human ventricular fibrillation (VF) that indicate the existence of universal fibrillatory mechanisms, opening the door to new therapeutic opportunities (Europace 2022;24\\[11\\]:1788-1799).",[129,130,131],"Atrial Fibrillation (AF)","Ablation Treatment","TerFib_Hyerarchy",[133,129,134,131],"Hierarchical organization of tissue excitation","Ablation","2026-02-18",{"date":137,"type":42},"2026-02-20",{"date":139,"type":42},"2025-01-20",{"date":141,"type":21},"2026-12-31",{"name":48,"class":49},{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":22,"phases":153,"briefSummary":154,"conditions":155,"keywords":160,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":170,"locationsCount":50},"100409069","value-of-screening-and-treatment-of-sahs-in-the-management-of-af-ablation-candidates-100409069","NCT04606693","Value of Screening and Treatment of SAHS in the Management of AF Ablation Candidates","Value of Screening and Treatment of Sleep Apnea-Hypopnea Syndrome in the Management of Atrial Fibrillation Ablation Candidates","SLEEP-AF","Inclusion Criteria:\n\n* Patients with paroxysmal or persistent atrial fibrillation\n* Recurrent atrial fibrillation despite treatment with at least one class I or III antiarrhythmic\n* No previous diagnosis of apnea-hypopnea syndrome\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years\n* Pregnant women\n* Doubts about the patient's ability to perform a home respiratory polygraphy\n* Doubts about the patient's ability to acquire rhythm records with the Kardia system (smartphone required)\n* Unavailability for follow-up at our center for at least 1 year.",{"count":152,"type":21},50,[62],"The present prospective cohort study (not randomized) analyses the value of screening and treatment of SAHS in the management of patients with AF refractory to antiarrhythmics drugs, potentially candidates for ablation.\n\nPatients at low risk of suffering from SAHS will follow conventional management of their AF, according to the usual criteria of the Arrhythmia Unit. Patients with high or intermediate risk of SAHS, will undergo respiratory polygraphy. If the result is positive, they will be treated as standard for this syndrome and their heart rate will be monitored for 3 months. After this, the patient's arrhythmic load will be reevaluated differentiating patients into two groups, those that must be ablated from those that have improved their condition and the clinical criteria is no longer ablation but follow-up.",[156,157,158,159],"Atrial Fibrillation Paroxysmal","Atrial Fibrillation, Persistent","Apnea Syndrome","Hypopnea Syndrome",[161,162,163,164],"Atrial Fibrillation","Apnea","Hypopnea","SAHS","2025-09-09",{"date":112,"type":42},{"date":168,"type":42},"2020-11-05",{"date":141,"type":21},{"name":48,"class":49},{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":22,"phases":181,"briefSummary":182,"conditions":183,"keywords":192,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":50},"100593147","clinical-impact-of-surgical-wound-morbidity-according-to-the-type-of-saphenous-vein-harvesting-technique-endoscopic-vs-open-in-patients-undergoing-myocardial-revascularization-surgery-100593147","NCT07002658","Clinical Impact of Surgical Wound Morbidity According to the Type of Saphenous Vein Harvesting Technique (Endoscopic vs. Open) in Patients Undergoing Myocardial Revascularization Surgery","Endoscopic Saphenous Vein Harvesting Versus Conventional Open Harvesting in Patients Undergoing Coronary Artery Bypass Grafting, Either Alone or in Combination With Another Cardiac Surgical Procedure, in Terms of the Clinical Impact of Surgical Wound Morbidity","EndOSiC","Inclusion Criteria:\n\n* Patients undergoing coronary artery bypass grafting (CABG), alone or in combination with other surgery (valve or arrhythmia surgery), with or without cardiopulmonary bypass (CPB), in which preoperative evaluation includes the plan to use a short saphenous vein segment (alone or in addition to arterial conduits).\n* Availability of a surgeon or cardiac surgery resident trained in endoscopic harvesting in the operating room.\n* Patients undergoing myocardial revascularization surgeries with or without extracorporeal circulation.\n* Patients undergoing concomitant cardiac valve replacement surgery, atrial fibrillation surgery, and others, in addition to CABG\n\nExclusion Criteria:\n\n* Emergent surgery or procedures performed during cardiorespiratory arrest\n* Myocardial revascularization with arterial grafts only\n* Presence of varicose veins\n* History of infrainguinal vascular surgery\n* Presence of ulcers and\u002For active infection in the lower limbs\n* Previous stroke with neurological sequelae in the legs\n* History of deep vein thrombosis in the legs\n* Pregnancy\n* Age under 18 years\n* Lack of signed informed consent",{"count":180,"type":21},356,[62],"The goal of this clinical trial is to compare two different techniques: endoscopic saphenous vein harvesting versus conventional open harvesting in patients undergoing coronary artery bypass grafting, either alone or in combination with another cardiac surgical procedure (valve surgery or arrhythmia surgery). The main questions the trial aims to answer are:\n\nDoes the endoscopic technique reduce surgical wound morbidity in terms of shorter hospital stays? Does endoscopic saphenous harvesting reduce the use of antibiotics for saphenectomy wound infections? Does the endoscopic technique reduce need for wound dressings due to necrosis and\u002For wound infection, and reduce need for analgesic treatment for wound pain? This prospective, randomized study will be conducted in the Cardiovascular Surgery Service at Hospital Clínico San Carlos.\n\nParticipants will be randomly assigned to a different saphenectomy technique. All patients will be assessed for saphenectomy wound complications upon discharge, and by phone call at 7 days, 1 month, and 3 months following the intervention.",[184,185,186,187,188,189,190,191],"CABG-patients","Saphenectomy","Endoscopic Surgery","Wound Complications","Antibiotic Use","Cardiac Surgery","Off Pump Coronary Artery Bypass Graft","Coronary Artery Bypass Graft With or Without ECC",[193,194,195,196],"endoscopic vein harvesting","CABG surgery","open vein harvesting","wound morbidity","2025-06-03",{"date":199,"type":42},"2025-06-06",{"date":201,"type":21},"2025-07-01",{"date":203,"type":21},"2026-08-01",{"name":48,"class":49},{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":212,"targetDuration":214,"studyType":215,"phases":4,"briefSummary":216,"conditions":217,"keywords":223,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":50},"100542868","registry-of-catheter-intervention-in-pulmonary-embolism-100542868","NCT06348459","Registry of Catheter Intervention in Pulmonary Embolism","RiTEP","Inclusion Criteria:\n\n* adult patients (aged 18 years old or older)\n* confirmed diagnosis of acute PE (on computed tomography or echocardiogram plus pulmonary angiography)\n* high-risk PE or intermediate-high risk according to ESC risk stratification in the 2019 guidelines (briefly, elevated cardiac biomarkers \\[troponin or N-terminal pro-B-type natriuretic peptide\\], and right ventricle to left ventricle ratio \\> 0.9 \\[on computed tomography or echocardiogram\\], and PE severity index III to IV or simplified PE severity index=1\n* eligibility for catheter-directed intervention\n\nExclusion Criteria:\n\n* unconfirmed diagnosis of PE\n* undefined risk stratification, and\n* PE with uncertain chronology or beyond seven days of symptom initiation.",{"count":213,"type":21},300,"2 Years","OBSERVATIONAL","Multicenter longitudinal observational ambispective (retrospective cases from 2014 and prospective from 2018 onwards) cohort study. The registry recruits a series of consecutive patients admitted for moderate-high risk or high-risk pulmonary embolism (according to 2019 European Society of Cardiology guidelines) treated invasively. This study aims to describe the acute management of the safety and effectiveness of different percutaneous interventions for acute pulmonary embolism.",[218,219,220,221,222],"Pulmonary Embolism","Pulmonary Embolism Acute Massive","Pulmonary Embolism Acute","Pulmonary Embolism and Thrombosis","Pulmonary Thromboembolisms",[224,225,226],"Aspiration Thrombectomy","Percutaneous Aspiration Thrombectomy","Local Thrombolysis","2025-04-23",{"date":229,"type":42},"2025-04-25",{"date":231,"type":42},"2018-09-18",{"date":233,"type":21},"2030-12-31",{"name":48,"class":49},{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":22,"phases":245,"briefSummary":246,"conditions":247,"keywords":253,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":269},"100539984","mechanical-insufflation-exsufflation-and-hypertonic-saline-in-nosocomial-bacterial-respiratory-tract-infection-100539984","NCT06310941","Mechanical Insufflation-exsufflation and Hypertonic Saline in Nosocomial Bacterial Respiratory Tract Infection","Aspiration of Bronchial Secretions With Mechanical Insufflation-Exsufflation and Hypertonic Saline in Bacterial Nosocomial Tracheobronchitis and Pneumonia in Intubated Patients.","ABSENTA","Inclusion Criteria:\n\n* Signed informed consent\n* Nosocomial pneumonia (vHAP or VAP) or nosocomial tracheobronchitis\n* Intubated with a cuffed endotracheal tube or tracheostomy cannula.\n\nExclusion Criteria:\n\n* Ominous prognosis\n* Frank hemoptisis\n* Barotrauma (pneumothorax or pneumomediastinum)\n* Bronchospasm (patients on bronchodilators for previous bronchospasm may be included\n* Unstable thoracic cage\n* Suspected unmonitored intracraneal hypertension",{"count":244,"type":21},100,[62],"Multicenter, randomized open label clinical trial to evaluate IEM and HS as concomitant therapy for respiratory tract infection in patients under artificial ventilation in the ICU.\n\nLung infection is a serious complication that may occur during hospital stay and may need artificial respiration or even develop during artificial ventilation for other causes.\n\nCurrent specific treatment consists of intravenous antibiotics. The current study evaluated whether aspiration and drainage of infected sputum helps curing this severe complication and whether nebulized HS has additional benefits, like loosening of secretions, eradicating bacteria or reducing inflammation.",[248,249,250,251,252],"Nosocomial Infection","Nosocomial Pneumonia","Tracheobronchitis","Mechanical Ventilation Complication","Endotracheal Intubation",[254,255,256,257,258,259,35,260],"mechanical insufflation-exsufflation","cough assist device","hypertonic saline","nosocomial respiratory tract infection","hospital-acquired pneumonia","tracheobronchitis","nebulization","2025-03-21",{"date":263,"type":42},"2025-03-26",{"date":265,"type":21},"2026-01-01",{"date":267,"type":21},"2027-12-30",{"name":48,"class":49},8,{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":274,"acronym":275,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":277,"enrollmentInfo":278,"targetDuration":4,"studyType":22,"phases":280,"briefSummary":282,"conditions":283,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":50},"100548216","phase-1-neoadjuvant-radio-chemotherapy-safety-pilot-study-in-patients-with-glioblastoma-100548216","NCT06418113","Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma","GLINERA","Inclusion Criteria:\n\n* Age between 18 and 75 years.\n* Unifocal disease.\n* Unilobar tumor.\n* Clinical-radiological diagnosis of supratentorial unicentric high-grade glioma, eligible for macroscopically complete resection.\n\nExclusion Criteria:\n\n* Multilobar tumor, interhemispheric or infratentorial extension, or multifocal disease.\n* Midline shift greater than 1 cm.\n* Intracranial hypertension symptoms requiring corticosteroid treatment.\n* Synchronous neoplasia.\n* Any contraindication for surgery, radiotherapy, or TMZ treatment.\n* Cognitive impairment.\n* Rejection of informed consent.\n* Inability to follow up for 2 years.\n* Women of childbearing potential according to the Clinical Trial Facilitation Group (CTFG) criteria. (https:\u002F\u002Fwww.hma.eu\u002Ffileadmin\u002Fdateien\u002FHuman\\_Medicines\u002F01-About\\_HMA\u002FWorking\\_Groups\u002FCTFG\u002F2020\\_09\\_HMA\\_CTFG\\_Contraception\\_guidance\\_Version\\_1.1.pdf)\n* Hypersensitivity to the active ingredient or any excipients of the investigational drug.","75 Years",{"count":279,"type":21},12,[281],"PHASE1","The goal of this clinical trial is to evaluate the safety and efficacy of neoadjuvant radiochemotherapy in the surgical resection of glioblastoma (GBM). The main questions it aims to answer are:\n\n* What is the safety profile of neoadjuvant radiochemotherapy in terms of neurological deficit, radionecrosis, edema, headache, wound dehiscence, infection, and cerebrospinal fluid fistula?\n* What is the efficacy of neoadjuvant radiochemotherapy in terms of progression-free survival, overall survival, cognitive function, and quality of life?\n\nParticipants will undergo the following tasks and treatments:\n\n* Stereotactic biopsy and diagnosis confirmation.\n* Conformal hypofractionated stereotactic radiotherapy with concurrent temozolomide.\n* Supramarginal resection guided by 5-ALA under intraoperative neurophysiological monitoring.\n* Maintenance temozolomide administration for 6 months.\n\nResearchers will compare the group receiving neoadjuvant radiochemotherapy to the control group following the standard Stupp protocol to assess safety and efficacy outcomes.",[284,285,286,287,288],"Glioblastoma","Glioblastoma Multiforme","Glioblastoma, IDH-wildtype","Radiotherapy; Complications","Cancer Brain","2024-05-13",{"date":291,"type":42},"2024-05-16",{"date":293,"type":42},"2024-03-21",{"date":295,"type":21},"2027-03-21",{"name":48,"class":49},{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":215,"phases":4,"briefSummary":306,"conditions":307,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":319,"locationsCount":50},"100426016","myocardial-ischemia-without-obstructive-coronary-stenoses-100426016","NCT04827498","Myocardial Ischemia Without Obstructive Coronary Stenoses","Myocardial Ischemia Without Obstructive Coronary Stenoses: A Prospective Observational Study With Invasive Coronary Pressure and Flow Measurements and Endothelial Function Test","Inclusion Criteria:\n\n* Written informed consent available.\n* Age ≥ 18 years.\n* Patient eligible for invasive physiological assessment with adenosine and \u002F or acetylcholine.\n\nExclusion Criteria:\n\n* Hemodynamic instability.\n* Anticipated technical issues for physiology wire measurements.\n* Culprit vessel of acute coronary syndrome\n* Contraindications for adenosine administration.\n* Contraindications for acetylcholine test.\n* Reduced life expectancy (less than 1 year).",{"count":305,"type":21},600,"Coronary-related myocardial ischemia can result from obstructive epicardial stenosis or non-obstructive causes including coronary microcirculatory dysfunction and vasomotor disorders. This prospective study has been created in order to provide knowledge in the field of non-obstructive coronary artery disease.",[308,309,310,311,312],"Myocardial Ischemia","Non-Obstructive Coronary Atherosclerosis","Microvascular Coronary Artery Disease","Vasospastic Angina","Myocardial Bridging","2021-04-23",{"date":315,"type":42},"2021-04-26",{"date":317,"type":42},"2017-11-08",{"date":233,"type":21},{"name":48,"class":49},""]